ChemBriefMerck Agrees to Acquire Bio-Techne for $11.3 Billion
Merck has agreed to acquire US life sciences firm Bio-Techne for $11.3 billion to bolster its portfolio in antibodies and cell therapy materials, with completion expected by 2027.
ccin · 2026-06-29 00:00